President Dave Rosa promoted to CEOCurrent CEO Gary Guthart to become executive chair of Intuitive’s boardCurrent Board Chair Craig Barratt to become lead independent director SUNNYVALE, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Intuitive (NASDAQ: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced the promotion of President Dave Rosa to chief executive officer, effective July 1, 2025. At that time, current CEO Gary Guthart will become the ...

Shares of Intuitive Surgical (ISRG) seem to gain momentum after declining for more than two months. The stock has risen 9.7% in the past month after declining more than 30% from its all-time high of $616 in January. The rally can be attributed to strong fundamentals despite tariff risks. Meanwhile, a trade deal between the United States and China has significantly lowered tariffs for 90 days, which must lower the anticipated tariff impact of 170 basis points on the cost of goods sold in 2025.Intuitive Surgi ...

Financial Data and Key Metrics Changes - The company reported a 19% year-over-year revenue growth, with a procedure growth rate of 17% [70][68] - The install base growth was 15%, indicating strong demand for the company's products [71] - Gross margins were noted as not perfect, with guidance set between 15% to 17% [71] Business Line Data and Key Metrics Changes - The SP product line saw a significant procedure growth of 94% year-over-year, indicating strong adoption [72] - General surgery has become the largest segment, with healthy growth across all segments [74] - The company has over 11,000 platforms operating in clinical environments, with a total of approximately 18 million procedures performed lifetime [57] Market Data and Key Metrics Changes - The company experienced strength in US General Surgery, with great adoption by general surgeons [65] - There has been a decrease in bariatric surgery due to the rise of GLP-1 drugs, but the company believes this will stabilize over time [63] - The company is present in 70 countries, indicating a broad market reach [85] Company Strategy and Development Direction - The company focuses on delivering value for patients and ensuring that healthcare providers receive value from their products [45] - There is an emphasis on expanding indications and launching new platforms, including the da Vinci V [60] - The company aims to achieve digital excellence and enhance its supply chain capabilities [91] Management's Comments on Operating Environment and Future Outlook - Management acknowledged environmental uncertainties in China and the impact of healthcare worker strikes globally [62][64] - The company is optimistic about the future, with a focus on innovation and growth despite current challenges [61] - Management highlighted the importance of a mission-driven employee population to achieve long-term goals [49] Other Important Information - The company has a strong Net Promoter Score of 75, indicating high customer satisfaction [87] - The company is committed to leveraging artificial intelligence and data analytics to improve surgical outcomes [103] Q&A Session All Questions and Answers Question: Are there any issues with tariffs affecting product sales in China? - The company faces a 125% tariff on products manufactured in the U.S. and imported into China, which has a significant financial impact [96] Question: What is being done to minimize the impact of tariffs? - The company is evaluating its supply chain operations and workflows to mitigate the impact of tariffs while waiting for the trade environment to stabilize [101] Question: How is the company leveraging AI and data analytics? - The company is focused on accessing high-quality data and using it for customer hospital analytics to optimize surgical outcomes [106][107] Question: What are the company's capital allocation priorities over the next two to three years? - The company prioritizes organic investment in the business, looking for technology acquisition opportunities, and returning excess cash to shareholders opportunistically [118]

Core Viewpoint - Intuitive has received FDA clearance for the da Vinci Single Port (SP) surgical system for transanal local excision/resection, enhancing its capabilities in colorectal surgery and offering a minimally invasive option for patients [1][4]. Company Overview - Intuitive is a global leader in minimally invasive care and robotic-assisted surgery, headquartered in Sunnyvale, California [8]. - The company has developed robotic-assisted technology for 30 years, with nearly 17 million procedures performed using its systems and approximately 90,000 surgeons trained [7]. Product Details - The da Vinci SP system is designed for precise navigation in narrow body cavities, allowing surgeons to control multiple instruments and a high-definition camera through a single entry point [2]. - This system addresses challenges in laparoscopic transanal minimally invasive surgery, improving ergonomics and access to lesions [3]. Clinical Impact - The FDA clearance for the da Vinci SP system is expected to positively impact patient outcomes by enabling better preservation of healthy tissue and accelerating recovery [4]. - The system supports a range of colorectal interventions, complementing Intuitive's existing offerings like da Vinci 5 and da Vinci Xi [5]. Evidence and Approval - Over 500 peer-reviewed publications support the safety and efficacy of the da Vinci SP system, which is also cleared for various procedures in urology and other surgical disciplines [6].

President Donald Trump's macroeconomic policies are creating significant uncertainty. His decision to impose sweeping tariffs on goods imported into the U.S. could harm the economy and specific corporations in ways that are scaring off investors. Some companies are already factoring the impact of tariffs on their financial results. One of them is Intuitive Surgical (ISRG 0.17%), a leader in medical devices. Despite the predicted effect of tariffs on the company's financial results for the rest of the year, ...

Core Insights - Robotic-assisted surgery is becoming essential in modern healthcare, with Intuitive Surgical and Stryker leading the market [1][2] - Both companies are heavily investing in innovation and global expansion, making them attractive for investors [2] Market Position and Differentiation - Intuitive Surgical pioneered robotic surgery with the da Vinci platform, while Stryker entered the market through the acquisition of Mako Surgical [3] - Intuitive holds nearly 80% of global surgical robotics volume, contrasting with Stryker's focus on orthopedic robotics with over 1.5 million Mako procedures [4] Revenue & Growth Trends - Intuitive's Q1 2025 revenues increased by 19% to $2.25 billion, with da Vinci procedures growing by 17% [5] - Stryker's MedSurg/Neurotechnology sales rose by 10.6% to $3.89 billion in Q4 2024, while Orthopaedics climbed by 10.8% to $2.55 billion [5] - The global robotic surgery market is projected to grow at a CAGR of 16.5% through 2029, driven by minimally invasive trends and aging populations [6] Estimates Comparison for ISRG & SYK - Zacks Consensus Estimate for ISRG's fiscal 2025 sales and EPS implies a year-over-year improvement of 15.6% and 7.1% respectively [7] - Zacks Consensus Estimate for Stryker's 2025 sales and EPS implies a year-over-year improvement of 8.6% and 10.4% respectively [10] Innovation Driving Growth - Intuitive Surgical is investing in next-generation platforms like the Ion endoluminal system for robotic bronchoscopy [12] - Stryker is enhancing its Mako SmartRobotics suite with AI-driven 3D CT planning and AccuStop haptic feedback [13] Price Performance & Valuation - Year-to-date price performance shows ISRG shares have lost 1.5%, while SYK shares have gained 1.8% [15] - Intuitive Surgical's dominance and sustainable revenue growth position it well, while Stryker's innovations fuel growth in the joint-replacement robotics niche [17] Zacks Rank & Style Score - Both companies currently hold a Zacks Rank 3 (Hold), complicating the investment decision [18] - ISRG's style score of 'F' indicates expensive valuation and low growth potential, while SYK's style score of 'C' suggests strong growth prospects [19]

Core Viewpoint - Intuitive Surgical reported strong quarterly earnings with a double beat on both revenue and earnings per share, but mixed guidance due to tariff uncertainties affecting future growth prospects [3][4][5]. Financial Performance - The company achieved earnings per share (EPS) of $1.81, exceeding estimates by $0.10 and reflecting a 20% year-over-year increase [3]. - Revenue for the quarter was $2.25 billion, surpassing estimates by 3.27% and showing a 19% year-over-year growth [3]. Guidance and Growth Expectations - Intuitive Surgical anticipates a procedure volume growth of 15% to 17%, an increase from the previous guidance of 13% to 16% [4]. - Despite the positive growth outlook, the company faces challenges from tariffs, which could offset this growth [5]. Tariff Impact - The company manufactures 98% of its Da Vinci systems in the U.S., but 70% of endoscopes and 80% of instruments and accessories are sourced from Europe and Mexico, respectively [6]. - Intuitive Surgical expects a non-GAAP gross margin of 65% to 66.5%, a decline of about 5% year-over-year, factoring in an estimated revenue impact of 1.7% due to tariffs [7]. Stock Performance and Analyst Ratings - The current stock price is $508.13, with a 12-month price target of $598.95, indicating a potential upside of 17.87% [8]. - The stock is trading at a forward P/E ratio of 75.8, which is considered expensive compared to the broader market but aligns with its five-year average [8]. - Analysts suggest a cautious approach, recommending waiting for the stock to break above the 50-day simple moving average before taking a long position [10]. Tariff Outlook - The company faces potential tariffs of 125% and 145% for imports and exports to China, 10% for European components, and 25% for certain products from Mexico [12].

Core Insights - Intuitive Surgical (ISRG) reported Q1 earnings for 2025 with mixed results compared to expectations [1] - Revenue for the quarter was $2.3 billion, exceeding analyst expectations by 3% and representing a year-over-year growth of 19% [1] - Earnings per share (EPS) for the quarter surpassed expectations by 5% [1]

Surgical Systems and Regulatory Approvals - As of March 31, 2025, the installed base of da Vinci SP surgical systems is 291, with FDA clearance for multiple procedures[110]. - The da Vinci 5 surgical system has an installed base of 509 as of March 31, 2025, and received FDA clearance for all surgical specialties except cardiac and pediatric[112]. - The company has commercialized various da Vinci surgical systems since 1999, with the latest being the da Vinci 5 surgical system launched in 2024[109]. - The Ion endoluminal system, launched in 2019, has received FDA clearance and various OUS regulatory approvals, expanding the company's offerings into diagnostic procedures[115]. - The company aims to expand the regulatory approvals for the da Vinci SP surgical system in international markets over time[111]. - The company plans to seek additional clearances and approvals for its Ion endoluminal system in OUS markets over time[115]. - The company obtained FDA clearance for the SP SureForm 45 stapler in March 2025, which is useful in thoracic and colorectal surgical procedures[149]. - The company received regulatory clearance for the da Vinci 5 surgical system in March 2024, which is expected to extend over several quarters for a phased launch[153]. - The Japanese Ministry of Health granted reimbursement for five additional da Vinci procedures in April 2024, including lobectomy for benign conditions[155]. - The company anticipates extended timelines for the introduction of new products due to increasingly stringent regulations[148]. - The company has obtained regulatory clearances for various products, including the E-200 generator and redesigned staplers, enhancing its product offerings[153]. Financial Performance and Revenue - Recurring revenue increased to $7.04 billion, representing 84% of total revenue in 2024, up from $5.94 billion (83%) in 2023 and $4.92 billion (79%) in 2022[129]. - Instruments and accessories revenue grew to $5.08 billion in 2024, compared to $4.28 billion in 2023 and $3.52 billion in 2022, reflecting continued procedure adoption[130]. - Service revenue reached $1.31 billion in 2024, an increase from $1.17 billion in 2023 and $1.02 billion in 2022, driven by a 15% growth in the installed base of da Vinci surgical systems[131]. - Systems revenue increased by 17% to $1.97 billion in 2024, following a flat performance of $1.68 billion in 2023[141]. - Total revenue for the three months ended March 31, 2025, increased by 19% to $2.25 billion compared to $1.89 billion for the same period in 2024[184]. - Product revenue rose by 20% to $1.89 billion for the three months ended March 31, 2025, compared to $1.58 billion for the same period in 2024[190]. - Service revenue increased by 16% to $363 million for the three months ended March 31, 2025, compared to $314 million for the same period in 2024[199]. - Operating income for Q1 2025 increased by 23% to $578 million compared to $469 million in Q1 2024[184]. - Net income attributable to Intuitive Surgical, Inc. was $698.4 million for the three months ended March 31, 2025, compared to $544.9 million for the same period in 2024, reflecting a 28% increase[185]. - The U.S. accounted for 68% of total revenue in the three months ended March 31, 2025, up from 66% in the same period in 2024[188]. Installed Base and Procedure Volume - The installed base of da Vinci surgical systems grew to approximately 9,902 as of December 31, 2024, compared to 8,606 in 2023 and 7,544 in 2022, indicating strong market adoption[131]. - The installed base of da Vinci surgical systems reached approximately 10,189 systems as of March 31, 2025, a 15% increase from 8,887 systems in Q1 2024[184]. - In 2024, approximately 2,683,000 surgical procedures were performed with da Vinci surgical systems, a 17% increase from 2023's 2,286,000 procedures[163]. - U.S. da Vinci procedures grew to approximately 1,757,000 in 2024, up 15% from 2023's 1,532,000 procedures, with general surgery being the largest specialty[164]. - OUS da Vinci procedures increased to approximately 926,000 in 2024, a 23% rise from 2023's 754,000 procedures, driven by urology and general surgery[165]. - Approximately 732,000 da Vinci procedures were performed in Q1 2025, a 17% increase from approximately 627,000 procedures in Q1 2024[184]. Tariffs and Trade Impact - The U.S. imposed a 25% tariff on imports from Mexico and Canada on February 1, 2025, but the impact on the company was not material due to USMCA certifications[117]. - A 10% universal tariff on imports not subject to USMCA was announced on April 2, 2025, affecting some raw materials and finished goods[118]. - The U.S. imposed tariffs up to 145% on imports from China on April 7, 2025, which may significantly impact the cost of da Vinci Xi surgical systems in China[119]. Operating Leases and Customer Trends - Total da Vinci system placements under operating lease arrangements increased to 864 in 2024, up from 704 in 2023 and 591 in 2022, with 51% of total placements under operating leases[135]. - Revenue from customer buyouts of leased systems was $109 million in 2024, up from $74 million in 2023 and $72 million in 2022, reflecting customer interest in ownership[140]. - Operating lease revenue was $654 million in 2024, compared to $501 million in 2023 and $377 million in 2022, indicating a growing trend in lease arrangements[135]. - Operating lease revenue was $195 million for the three months ended March 31, 2025, compared to $148 million for the same period in 2024[195]. Research and Development - The company anticipates continued substantial investments in research and development to support product development initiatives[211]. - Research and development expenses rose by 11% to $316.2 million in Q1 2025, compared to $284.5 million in Q1 2024[209]. Financial Reporting and Accounting - The financial statements are prepared in accordance with GAAP, requiring estimates and judgments that affect reported amounts of assets, liabilities, revenues, and expenses[229]. - There have been no new or material changes to the critical accounting estimates since the Annual Report on Form 10-K for the fiscal year ended December 31, 2024[229]. - Actual results may differ from estimates under different assumptions or conditions, highlighting the inherent uncertainty in financial reporting[229].

Core Insights - Intuitive Surgical Inc reported first-quarter 2025 revenue of $2.25 billion, exceeding analyst estimates of $2.19 billion, with a year-over-year increase of 19% [1] - The company placed 367 da Vinci surgical systems in the quarter, up from 313 in the same quarter of the previous year, leading to a total installed base of 10,189 systems, a 15% increase year-over-year [1] - Adjusted earnings for the first quarter were $1.81 per share, surpassing analyst expectations of $1.72 per share [2] Revenue and Growth - Worldwide da Vinci procedures increased by approximately 17% year-over-year, with guidance for a full-year increase of 15%-17% [1][2] - The company expects a gross profit margin of 65% to 66.5% in 2025, accounting for an estimated 1.7% impact from tariffs [3] Analyst Perspectives - Analysts believe the stock deserves a premium multiple due to elevated procedure growth and a new product cycle that could drive significant revenue and EPS growth [4] - Concerns about macro dynamics and potential Medicaid cuts may impact stock performance, but management noted that U.S. capital spending remains stable [4][5] - The company's leasing model is aiding hospitals in managing tight budgets, although potential Medicaid cuts could significantly affect hospital finances [5] Financial Position - The company has a strong cash position of $9.1 billion and zero debt, providing flexibility for share buybacks [6] - Stifel maintains a price target of $670 with a Buy rating, while Truist Securities has adjusted its price target from $605 to $590 but maintains a Buy rating [3][6] Stock Performance - ISRG stock increased by 2.47% to $490.58 [7]